Product Name :
HMN-176
Description:
HMN-176 is a stilbene derivative which inhibits mitosis, interfering with polo-like kinase-1 (plk1), without significant effect on tubulin polymerization.
CAS:
173529-10-7
Molecular Weight:
382.43
Formula:
C20H18N2O4S
Chemical Name:
N-{6-[2-(1-hydroxy-1,4-dihydropyridin-4-ylidene)ethylidene]cyclohexa-2,4-dien-1-ylidene}-4-methoxybenzene-1-sulfonamide
Smiles :
COC1C=CC(=CC=1)S(=O)(=O)N=C1C=CC=CC1=CC=C1C=CN(O)C=C1
InChiKey:
MYEJOKLXXLVMPR-RPBJWCAZSA-N
InChi :
InChI=1S/C20H18N2O4S/c1-26-18-8-10-19(11-9-18)27(24,25)21-20-5-3-2-4-17(20)7-6-16-12-14-22(23)15-13-16/h2-15,23H,1H3/b17-7+,21-20-
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
HMN-176 is a stilbene derivative which inhibits mitosis, interfering with polo-like kinase-1 (plk1), without significant effect on tubulin polymerization.|Product information|CAS Number: 173529-10-7|Molecular Weight: 382.43|Formula: C20H18N2O4S|Chemical Name: N-{6-[2-(1-hydroxy-1,4-dihydropyridin-4-ylidene)ethylidene]cyclohexa-2,4-dien-1-ylidene}-4-methoxybenzene-1-sulfonamide|Smiles: COC1C=CC(=CC=1)S(=O)(=O)N=C1C=CC=CC1=CC=C1C=CN(O)C=C1|InChiKey: MYEJOKLXXLVMPR-RPBJWCAZSA-N|InChi: InChI=1S/C20H18N2O4S/c1-26-18-8-10-19(11-9-18)27(24,25)21-20-5-3-2-4-17(20)7-6-16-12-14-22(23)15-13-16/h2-15,23H,1H3/b17-7+,21-20-|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO : ≥ 30 mg/mL (78.45 mM).|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|HMN-176 (2.5 μM) greatly increases the duration of mitosis in hTERT-RPE1 and CFPAC-1 Cell lines. The effect of HMN-176 on spindle morphology does not appear to be related to effects on microtubule polymerization. HMN-176 (2.5, 0.25, and 0.025 μM) inhibits aster formation in a concentration dependent manner.{{Atropine} web|{Atropine} Neuronal Signaling|{Atropine} Technical Information|{Atropine} References|{Atropine} manufacturer|{Atropine} Epigenetic Reader Domain} HMN-176 (0.{{Reverse T3} web|{Reverse T3} Vitamin D Related/Nuclear Receptor|{Reverse T3} Biological Activity|{Reverse T3} In Vivo|{Reverse T3} custom synthesis|{Reverse T3} Cancer} 1, 1.PMID:32930050 0, or 10.0 µg/mL) demonstrates inhibitory effects in multiple tumors, with notable activity seen in breast, nonsmall-cell lung, and ovarian cancer specimens. HMN-176 demonstrates activity towards 63% of the breast (5/8), 67% of the non-small cell lung (4/6), and 57% of the ovarian (4/7) tumor specimens treated with 10.0 µg/mL. HMN-176 shows potent cytotoxicity, with a mean IC50 value of 118 nM. HMN-176 displays similar cytotoxicity against tumors with various characteristics from different organs. Treatment with 3 μM HMN-176 suppresses the expression of MDR1 mRNA by 56%. HMN-176 has no significant effect on the residual promoter activity.|In Vivo:|After p.o. of HMN-214 to male rats, the prodrug is not detected in the plasma, while plasma levels of HMN-176 peaks at 2 h and gradually decreases thereafter.|Products are for research use only. Not for human use.|